Monitor emerging drug resistance
in real time
Malaria speciation and drug resistance
screening in minutes, sample to result
Resistance to anti-malaria drugs
is spreading
Accurate results in minutes
in the hospital, clinic or field
Placing gold standard testing into the
hands of frontline healthworkers
Every minute a child dies of malaria
Every minute a child dies of malaria
One Device, Endless Possibilities™
Q-POC™: The Handheld Laboratory

The NANOMAL PROJECT

The Future of malaria diagnosis

Our FP7 European Union funded NanoMal Consortium is developing a handheld laboratory that will deliver complex malaria diagnostics in minutes for a few dollars in any setting across the globe.

Making malaria elimination possible

Our handheld laboratory will provide frontline healthworkers with the definitive tool to diagnose,
manage and monitor malaria and drug resistance.

  • Results in 10-15 minutes
  • Malaria diagnosis & drug resistance testing
  • Directs right first time prescribing
  • Handheld, user friendly, low cost
  • Mobile data connection

The Nanomal Consortium partners are: 
St George's University London | QuantuMDx Group | The Karolinska Insititute | Tubingen University.

St Georges University London is a pertner in the Nanomal ProjectQuantuMDx are partners in the Nanomal ProjectKarolinska Partners for the Nanomal ProjectTubingen University is a pertner in the Nanomal Project

 

CEO Elaine Warburton OBE attended BIO CEO & Investor Conference as part of a UKTI Market Visit

Mayor of London Boris Johnson was one of many attendees excited about the Q-POC device.

CSO Jonathan O’Halloran chaired the Point of Care Diagnostics Symposia at Molecular Medicine Tricon in San Francisco...

and was back in the UK for a half marathon the following day!

Business Development Executive Maggie Love is looking forward to the Africa Healthcare Summit

including meetings with Ministries of Health.

CEO Elaine Warburton will speak at the Royal Society of Medicine’s Recent Developments in Digital Health

this week, giving attendees a glimpse of the future of diagnostics.

QuantuMDx invited to Wellcome Trust’s Review of Antimicrobial Resistance

Jonathan O’Halloran has been invited to sit on a diagnostics panel at the Wellcome Trust’s first event of the Review of Antimicrobial Resistance, an event tackling a crisis for the health and wealth of nations.
Read more >

QuantuMDx attended JP Morgan Healthcare Conference in San Francisco

If you would like to meet, please email Maggie Love - info@quantumdx.com

QuantuMDx attended Arab Health in Dubai

We were struck by the energy of the place. We had preliminary discussions with several large multinational electronics companies regarding their digital health information solutions, and hope that further discussion with them will help to shape our vision for the Internet of Life. We were particularly impressed by the many forward-thinking private hospitals in attendance who understand the benefits of point of care not only to the bottom line but also to patient outcomes. We look forward to being part of the event next year, and returning to Dubai’s indoor ski slope!

Double honours as CSO named ‘Pioneer’ and CEO one of ‘50 Movers & Shakers in BioBusiness 2014’

CEO Elaine Warburton was named a BioBusiness Mover & Shaker by BioBeat in a report on women challenging the status quo in Britain, while CSO Jonathan O’Halloran was titled ‘Pioneer’ by Connected World for his Internet of Life vision.

QuantuMDx exhibited at MEDICA 2014

With a stand at E22 in Hall 1, and non-working demo Q-POC devices on hand. On Thursday at 4pm a stand party was held sharing “A Taste of North East England”, with Newcastle Brown Ale and Durham Gin available.

FIND and QuantuMDx partnering to developing breakthrough technology for tuberculosis detection and drug resistance determination

FIND, a Geneva-based non-profit organization and QuantuMDx Group, a British medical device developer are joining forces in developing a paradigm changing solution for the combined detection of and drug susceptibility determination for the causative agent for tuberculosis. Based on the molecular detection of an extensive set of genetic markers by the simple handheld Q-POC™ device developed by QuantuMDx, the time for full antimycobacterial resistance profiling will be reduced from weeklong to less than half an hour.

QuantuMDx announce prototype handheld lab for 15 minute DNA-based diagnosis

At the TEDMED 2014 conference, medical device developers QuantuMDx Group announced the successful production of their first fully-integrated sample-to-result working prototype of Q-POC™, a handheld lab that delivers your DNA-based medical diagnosis in minutes. The Group believes the future of disease management and drug resistance monitoring is networked geo-stamped data, a functionality provided by the handheld Q-POC™ device. Rapid and low cost testing will enable continuous monitoring of disease and antimicrobial resistance throughout populations, as well as surveillance for emerging novel pathogen threats such as Ebola.